Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis
Authors
Keywords
-
Journal
CALCIFIED TISSUE INTERNATIONAL
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-03-01
DOI
10.1007/s00223-022-00962-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
- (2021) Athanasios D. Anastasilakis et al. Journal of Clinical Medicine
- Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases
- (2021) Peter Burckhardt et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2‐Year Randomized Study
- (2021) Anne Sophie Sølling et al. JOURNAL OF BONE AND MINERAL RESEARCH
- The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation
- (2021) Polyzois Makras et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence
- (2021) Giorgia Grassi et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Preventing Rebound-Associated Fractures after Discontinuation of Denosumab Therapy: A Position Statement from the Health Insurance Committee of the Korean Endocrine Society
- (2021) Bu Kyung Kim et al. Endocrinology and Metabolism
- A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains
- (2020) Judith Everts‐Graber et al. JOURNAL OF BONE AND MINERAL RESEARCH
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS—2020 UPDATE
- (2020) Pauline M. Camacho et al. Endocrine Practice
- Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis
- (2020) Kosuke Ebina et al. Modern Rheumatology
- Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS
- (2020) Elena Tsourdi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Stopping Denosumab
- (2019) Olivier Lamy et al. Current Osteoporosis Reports
- Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis
- (2019) Patricia Barrionuevo et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline
- (2019) Richard Eastell et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐year Clinical Trial
- (2019) Athanasios D. Anastasilakis et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Bone Mineral Density After Transitioning From Denosumab to Alendronate
- (2019) David Kendler et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider
- (2019) Liana Tripto-Shkolnik et al. BONE
- Factors related to intentional non-initiation of bisphosphonate treatment in patients with a high fracture risk in primary care: a qualitative study
- (2018) Karin M. A. Swart et al. BMC Family Practice
- Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
- (2017) Steven R Cummings et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Observations following discontinuation of long-term denosumab therapy
- (2017) M. R. McClung et al. OSTEOPOROSIS INTERNATIONAL
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
- (2017) Henry G Bone et al. Lancet Diabetes & Endocrinology
- Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials
- (2015) Ana Boquete-Castro et al. CLINICAL ORAL IMPLANTS RESEARCH
- Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures
- (2014) Carolyn J. Crandall et al. ANNALS OF INTERNAL MEDICINE
- The Risk of Osteonecrosis of the Jaws in Taiwanese Osteoporotic Patients Treated With Oral Alendronate or Raloxifene
- (2014) Wei-Yih Chiu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research
- (2013) Elizabeth Shane et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Propensity Scores: Uses and Limitations
- (2012) Kristin L. Sainani PM&R
- Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
- (2011) Henry G. Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Vertebral fracture assessment using a semiquantitative technique
- (2010) Harry K. Genant et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
- (2009) Steven R. Cummings et al. NEW ENGLAND JOURNAL OF MEDICINE
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
- (2009) Peter C. Austin STATISTICS IN MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now